Lipid nanoparticles for paediatric osteosarcoma treatment
Materias Investigacion::Ciencias de la Salud::Oncología
Materias Investigacion::Ciencias de la Salud::Pediatría
Issue Date: 
Defense Date: 
GONZÁLEZ FERNÁNDEZ, Yolanda. “Lipid nanoparticles for paediatric osteosarcoma treatment”. Blanco Prieto, M.J. y Patiño García, A. (dirs.). Tesis doctoral. Universidad de Navarra, Pamplona, 2017.
Osteosarcoma (OS) is the primary bone tumour most frequent in the paediatric population. It usually appears in the limbs, although the presence of non-visible micrometastases in the lungs is assumed at the time of diagnose. Nanomedicine has emerged as a promising alternative to conventional therapies for cancer treatment. Particularly lipid nanoparticles (LN) present several advantages over conventional therapies: for instance, they increase the bioavailability of the encapsulated drugs, they protect drugs from degradation, they avoid their indiscriminate distribution, and they can be orally administered. On the basis of the foregoing, the initial hypothesis of the present work is: The use of LN for the encapsulation of drugs currently used for OS treatment (methotrexate and doxorubicin) may circumvent their associated toxicity and increase their in vivo bioavailability and efficacy. Besides, the inclusion of new drugs for OS therapy, such as edelfosine, would offer alternative treatments for OS patients. Based on this premise the main objective of the present work was to design, develop and optimize LN for the oral delivery of edelfosine, methotrexate and doxorubicin, and to evaluate their in vitro and in vivo efficacy against OS murine models.

Files in This Item:
2,45 MB
Adobe PDF
The file will be visible since 11-Apr-2019

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.